Bausch + Lomb Corporation

BLCO.TO·Toronto·Healthcare
Compare
23.13−0.38 (−1.62%)today
At close: Oct 16, 1:19 PM EDT · May be delayed up to 15 min · CAD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close23.51
Open23.56
Day range23.1123.56
52-week range20.2525.70
Off day high−1.83%
Off 52-week high−10.00%
Volume601
Avg. volume (3M)1.70K
Market cap8.26B
EPS (TTM)-0.6800
Forward P/E14.64
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.56
Shares outstanding357.17M
Short interest0.12% of float
Earnings dateOct 28, 2026
Analyst target25.21
Profit margin−3.21%

Against its peers

Compare in full ›
BLCO.TO ALC COO STAA WRBY BAX
Market cap 8.26B 31.99B 11.02B 1.07B 2.89B 13.07B
P/E (TTM) — 50.1 19.9 265.9 389.0 —
Forward P/E 14.6 16.7 12.3 19.1 38.0 12.4
Price/book 0.9 1.5 1.3 2.9 7.3 2.1
Dividend yield — 0.54% — — — 0.16%
1-year change +4.57% −12.30% −20.24% −16.00% +13.32% +9.30%
Today −1.62% −0.60% +0.94% −4.45% −5.08% −1.86%

The closest companies by business and industry (Medical Instruments & Supplies). Prices may be delayed up to 15 min.

Latest news

All BLCO.TO news ›
Rochester Business Journal·Positive

Leadership change at Bausch + Lomb as Saunders exits

Bausch + Lomb Corp. has appointed Thomas J. Appio interim CEO, succeeding Brent Saunders, who has led the company since 2023. Saunders and the board mutually agreed that he would depart from the company. Saunders previously served as the…

Eyes On Eyecare·Positive

Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation

Bausch + Lomb Corporation is making headway in developing an investigational oral treatment for dry age-related macular degeneration (AMD) following a “constructive” meeting with the FDA. Not to worry, we’ve got a few details—starting with…

The Manila Times·Negative

Bausch + Lomb CEO departs, interim chief named

BAUSCH + Lomb said on Monday that CEO Brent Saunders will leave the eye-care company by mutual agreement with its board, sending its US-listed shares down more than 7 percent. Chairman Thomas Appio was named interim CEO, effective…

FINCHANNEL·Negative

Bausch + Lomb shares fall as CEO Saunders departs

Bausch + Lomb appointed Chairman Thomas J. Appio as interim chief executive on October 12, replacing Brent Saunders, while the eye health company and parent Bausch Health said they expect to increase their full-year earnings guidance. The…

Stock Titan·

Bausch + Lomb CEO Brent Saunders to depart October 12

UnitedHealth Group Reports Third Quarter 2026 Results Saunders’ separation agreement provides a $75.5 million aggregate lump-sum payment, contingent on an executed and unrevoked release. Bausch + Lomb Corporation (BLCO) announced CEO and…

Seeking Alpha·Positive

Bausch + Lomb names Thomas Appio interim CEO, signals guidance hike

Bausch + Lomb names Thomas J. Appio interim CEO as Brent Saunders departs; companies may raise 2026 adjusted EBITDA guidance ahead of Oct. - Bausch + Lomb (BLCO:CA) appointed chairman Thomas J. Appio as interim CEO, effective immediately,…

From articles in the 4Search news index.

In the news

28mentions in 30 days
28with it in the headline
Mixedsentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.